Middle East Cancer Therapeutics Market Report (2021–2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The cancer therapeutics market size is expected to reach US$ 3,665.51 million by 2031 from US$ 1,808.60 million in 2024. The market is estimated to record a CAGR of 10.71% from 2025 to 2031.

Executive Summary and Middle East Cancer Therapeutics Market Analysis:

The cancer therapeutics market in Middle East is experiencing significant growth driven by several key factors, including significant advancements in healthcare infrastructure and an increase in the prevalence of cancer. The region is known for its economic wealth, and it has made strides in developing its healthcare sector to meet the rising demands of its aging population. Owing to the continuous evolution of healthcare systems, rising cancer incidence, burgeoning government support, and an increased focus on cancer care, the Middle East region is experiencing substantial growth in the cancer therapeutics market. The demand for innovative cancer treatment modalities such as immunotherapies and personalized medicine is rising in Middle East countries, and investments in healthcare systems and awareness programs are aiding in improved access to these therapies.

Middle East Cancer Therapeutics Market Segmentation Analysis:

Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.

By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.

Middle East Cancer Therapeutics Market Outlook

A significant rise in cancer cases in the region drives the need for cancer therapeutics in Middle East region. According to the GLOBOCAN 2022 Data, in 2022, ~4,347 new cancer cases were detected in Kuwait, among which breast cancer was the most prominent type, followed by colorectum cancer. As per the same source, the country recorded ~892 new breast cancer cases, representing 20.5% of all registered cases. The five-year prevalence rate for breast cancer in all ages was 211.30 per 100,000 population. It was also the major cause of cancer deaths in women, as it caused ~255 deaths in 2022.

Governments of various countries of the Middle East are investing heavily in healthcare infrastructure and cancer control programs. For instance, Qatar's government prioritizes healthcare as part of its National Vision 2030, which includes strengthening the country's healthcare system and promoting medical research. The Qatar Cancer Society, alongside institutions such as Hamad Medical Corporation (HMC), plays a crucial role in raising awareness and providing care. HMC's National Center for Cancer Care and Research (NCCCR) is a key facility offering advanced treatments, including chemotherapy, radiotherapy, and clinical trials for cancer patients. The Qatar Cancer Plan 2023–2026 sets out clear strategic objectives and deliverables to be accomplished by the end of 2026. These include a focus on key areas such as the development of palliative homecare services and precision medicine in cancer care. The cancer therapeutics market is expected to continue expanding in Qatar with these government initiatives and the burgeoning cancer burden.

Middle East Cancer Therapeutics Market Country Insights

Based on region, the Gulf Cooperation Council (Middle East) cancer therapeutics market is further segmented into Saudi Arabia, UAE, Kuwait, Oman, Qatar, and Bahrain. Saudi Arabia held the largest share in 2024.

The growth of the cancer therapeutics market in Saudi Arabia is driven by rising cancer incidence, growing healthcare infrastructure, and an increasing aging population. Saudi Arabia has been experiencing an upsurge in the incidence of cancer; the number of cancer-related deaths has also increased in the country. As per GLOBOCAN 2020 data, the country recorded ~27,885 new cancer cases, and the number is expected to rise to 60,429 by 2040. Also, the number of people aged 80 or more is expected to reach 1.6 million, i.e., 4% of the total population by 2050. Lifestyle changes such as increased tobacco use and poor dietary habits further elevate cancer risk in the Saudi population.

Middle East Cancer Therapeutics Market Company Profiles

Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.

Middle East Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

Industry stakeholders:

Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:

The World Bank World Development Indicators: Arab World World Health Organization Regional Office for Eastern Mediterranean (WHO-EMRO) Global Cancer Observatory Qatar Cancer Society Show more